Modulation of innate immunity by HIV-1 gene products

Information

  • Research Project
  • 6589904
  • ApplicationId
    6589904
  • Core Project Number
    R21AI054215
  • Full Project Number
    1R21AI054215-01
  • Serial Number
    54215
  • FOA Number
    PA-02-46
  • Sub Project Id
  • Project Start Date
    4/15/2003 - 21 years ago
  • Project End Date
    3/31/2005 - 19 years ago
  • Program Officer Name
    WASSEF, NABILA M.
  • Budget Start Date
    4/15/2003 - 21 years ago
  • Budget End Date
    3/31/2004 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    -

Modulation of innate immunity by HIV-1 gene products

DESCRIPTION (provided by applicant): The immunopathogenesis associated with HIV-1 infection is characterized by several functional abnormalities of immune system cell populations and by a progressive decline in the numbers and functions of CD4+ T lymphocytes. In spite of many efforts, the mechanisms ultimately leading to the development of AIDS have not yet been fully elucidated. The general goal of this proposal is to characterize early HIV interactions as well as bystander effects of HIV-1 gene products on cell populations of the innate immunity system to the aim of defining novel mechanisms involved in viral persistence and immune system dysfunctions relevant to the comprehension of immunopathogenesis of AIDS. Based on the working hypothesis that the functional outcome of the immune response is likely to be determined by the type of innate immune response elicited, the project foresees the following objectives: i) Determine the effects of early HIV interaction with macrophages and DCs on the expression/activation of Toll-like receptors ii) Define the molecular signals triggered by early HIV/target cell interactions and their role in HIV mediated functional cell alterations iii) Characterize the immunomodulatory activities of HIV-1 Vpr accessory protein on effector cells linking innate and adaptive responses. It is expected that this research could provide the basis for a novel interpretation of important aspects of immunopathogenesis which may be critical to the ultimate development of effective prophylactic and therapeutic interventions.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R21
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    162000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:162000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ISTITUTO SUPERIORE DI SANITA
  • Organization Department
  • Organization DUNS
    436318315
  • Organization City
    ROME
  • Organization State
  • Organization Country
    ITALY
  • Organization Zip Code
    00161
  • Organization District
    ITALY